US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist
  • 2.240
  • +0.040+1.82%
Close Nov 29 13:00 ET
  • 2.270
  • +0.030+1.34%
Post 17:01 ET
184.91MMarket Cap-881P/E (TTM)

About Editas Medicine Company

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolEDIT
Company NameEditas Medicine
Listing DateFeb 3, 2016
Issue Price16.00
Founded2013
CEODr. Gilmore O’Neill, M.B.
MarketNASDAQ
Employees265
Fiscal Year Ends12-31
Address11 Hurley Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-401-9000
Websitehttp://www.editasmedicine.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Gilmore O’Neill, M.B.
  • Director, Chief Executive Officer and President
  • 2.39M
  • Erick J. Lucera, C.F.A.
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • 2.22M
  • Linda Burkly
  • Executive Vice President and Chief Scientific Officer
  • 1.54M
  • Baisong Mei, M.D.,PhD
  • Senior Vice President and Chief Medical Officer
  • 1.14M
  • Emma Reeve
  • Chairman of the Board
  • 238.24K
  • Dr. Meeta Chatterjee, PhD
  • Independent Director
  • 205.56K
  • Andrew J. Hirsch
  • Independent Director
  • 210.56K
  • Dr. Jessica Hopfield, PhD
  • Independent Director
  • 231.07K
  • Dr. Elliott M. Levy, M.D.
  • Independent Director
  • 264.88K
  • Dr. David T. Scadden, M.D.
  • Independent Director
  • 213.06K
  • Bernadette M. Connaughton
  • Independent Director
  • 215.06K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Gene Editing
Gene Editing
Intraday+0.54%